查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1986884

Duchenne氏肌肉失養症治療市場規模、佔有率、趨勢和預測：按產品類型、治療方法、最終用戶和地區分類，2026-2034 年

Duchenne Muscular Dystrophy Drugs Market Size, Share, Trends and Forecast by Product Type, Therapeutic Approach, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球Duchenne氏肌肉失養症治療市場規模為27億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以8.90%的複合年成長率成長，到2034年達到60億美元。目前，北美市場主導地位，預計2025年將佔全球市場佔有率的35%。該地區受益於完善的醫療保健基礎設施、支持孤兒藥認定的健全法規結構、對罕見疾病研究的大量投入以及廣泛的保險覆蓋，這些都使患者更容易獲得先進的治療方法。所有這些因素都促進了Duchenne氏肌肉失養症市場佔有率的成長。

全球Duchenne氏肌肉失養症)治療市場的主要驅動力是Duchenne氏肌肉失養症盛行率的上升以及醫護人員和看護者對早期診斷和介入意識的增強。分子生物學、基因工程和精準醫學的進步推動了包括基因療法和反義寡核苷酸在內的創新治療方法的開發，從而拓展了治療選擇。此外，政府對罕見疾病研究投入的增加，以及孤兒藥認定和加速核准等有利的監管途徑，鼓勵製藥公司加大對 DMD 治療藥物研發的投資。在學術機構、生技公司和病患權益組織合作的支持下，臨床試驗管線的擴展正在加速新化合物從臨床前階段向商業化階段的轉化，從而推動了所有主要地區Duchenne氏肌肉失養症治療市場的成長。

由於多種因素，美國正崛起為Duchenne氏肌肉失養症)治療市場的領先地區。美國擁有強大的藥物研發生態系統，頂尖的學術醫療中心和生技公司在神經肌肉疾病治療方法投入了大量資源。聯邦政府的支持性政策，包括《孤兒藥法案》和快速核准系統，正在加速DMD等罕見疾病藥物的研發。例如，美國食品藥物管理局 (FDA) 於2024年擴大了ELEVIDYS（delandistrogen moxeparbovec）的核准範圍，使其可用於治療4歲及以上、已確診攜帶DMD基因突變的行走和非行走患者。此外，完善的新生兒篩檢計畫和先進的診斷能力能夠早期發現受影響的患者，從而支持及時治療性介入，並推動全美市場成長。

Duchenne氏肌肉失養症症治療市場趨勢：

基因治療方法的進展

基因治療技術的快速發展正在顯著改變Duchenne氏肌肉失養症的治療格局。研究人員正利用腺結合病毒（AAV）載體將功能性Dystrophin基因直接遞送至肌肉組織，旨在部分恢復Dystrophin的產生並延緩疾病進展。這種單次靜脈輸注療法標誌著模式轉移，從慢性症狀治療轉向了可能持續緩解疾病的干涉措施。此外，基於CRISPR的基因編輯平台的發展為精準矯正Dystrophin基因突變開闢了新的途徑，目前已有多個候選藥物進入臨床前評估階段。例如，2025年6月，美國食品藥物管理局（FDA）授予PBGENE-DMD罕見兒童疾病認定，這是由Precision BioSciences公司利用ARCUS平台開發的體內基因編輯療法。該療法針對Dystrophin基因的第45至55號外顯子，可望使高達60%的杜氏肌肉營養不良症患者受益。這些突破性進展正在吸引全球範圍內的巨額投資和監管支援。

擴大新型皮質類固醇的使用範圍

新一代皮質類固醇的問世，憑藉其更優的安全性，正在改變杜氏肌肉營養不良症（DMD）患者的治療標準，並提振Duchenne氏肌肉失養症治療市場前景。多年來，潑尼松和地夫可特等傳統皮質類固醇一直是DMD治療的基礎。它們在維持肌肉功能和延緩行走能力喪失方面取得了顯著療效。然而，長期使用這些藥物會引發人們對嚴重副作用的擔憂，例如發育不良、骨骼密度下降和行為改變。因此，新型分離性皮質類固醇應運而生，它們透過選擇性受體調節，在維持抗發炎作用的同時，最大限度地減少這些副作用。例如，2025年11月，Santella Pharmaceuticals公司公佈了vamorolone（Agamree）的GUARDIAN試驗5年追蹤數據，結果顯示其療效與標準皮質類固醇相當，且DMD患者的椎體骨折發生率顯著降低，生長曲線也得到改善。這些臨床優勢提高了全球處方醫師的信任度，並促使更多患者接受該療法。

擴大非類固醇抗發炎藥（NSAID）治療選擇

非類固醇類治療方法的核准和研發正在豐富Duchenne氏肌肉失養症)治療市場的發展趨勢。組蛋白去乙醯化酶抑制劑是一種基於全新作用機制的新型療法，其靶向Dystrophin缺乏引起的下游病理過程，例如慢性發炎、肌肉再生障礙和進行性性脂肪浸潤。這些藥物透過調節基因表現來恢復營養不良肌肉組織中必要的細胞修復機制，產生與潛在基因突變類型無關的療效。針對所有 DMD 突變類型治療方法有效治療方法尤其重要，因為它將合格患者群體擴展到突變特異性治療方法之外。例如，2025 年 4 月，歐洲藥品管理局 (EMA) 人用藥品委員會 (CHMP) 通過了一項積極意見，建議有條件地核准Italfarmaco 公司開發的 Duvyzat（吉比司他）上市，用於治療 6 歲及以上能夠行走的 DMD 患者。此前，FDA 於 2024 年 3 月核准了吉比司他，使其成為皮質類固醇療法的補充治療選擇。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 調查方法

第3章執行摘要

第4章：引言

第5章：Duchenne氏肌肉失養症治療的全球市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依產品類型分類

  • 皮質類固醇
    • 主要部分
      • 潑尼松龍
      • 強的松
      • 德弗拉扎科特
  • 疼痛管理藥物

第7章 市場區隔：依治療方法分類

  • 突變抑制
  • 埃克森美孚跳過
  • 類固醇療法

第8章 市場區隔：依最終用戶分類

  • 醫院
  • 診所
  • 居家照護設施

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 促進因素、阻礙因素和機遇

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • FibroGen Inc.
    • Italfarmaco SpA
    • NS Pharma Inc.（Nippon Shinyaku Co. Ltd.）
    • PTC Therapeutics Inc.
    • Santhera Pharmaceuticals
    • Sarepta Therapeutics Inc.
Product Code: SR112026A6715

The global duchenne muscular dystrophy drugs market size was valued at USD 2.7 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 6.0 Billion by 2034, exhibiting a CAGR of 8.90% from 2026-2034. North America currently dominates the market, holding a market share of 35% in 2025. The region benefits from a well-established healthcare infrastructure, strong regulatory frameworks supporting orphan drug designations, high levels of investment in rare disease research, and widespread insurance coverage that facilitates patient access to advanced therapies, all contributing to the duchenne muscular dystrophy drugs market share.

The global duchenne muscular dystrophy drugs market is primarily driven by the rising prevalence of Duchenne muscular dystrophy and growing awareness among healthcare providers and caregivers regarding early diagnosis and intervention. Advances in molecular biology, genetic engineering, and precision medicine are enabling the development of innovative therapeutic modalities, including gene therapies and antisense oligonucleotides, which are broadening the treatment landscape. Furthermore, increased government funding for rare disease research, coupled with favorable regulatory pathways such as orphan drug designations and accelerated approvals, is encouraging pharmaceutical companies to invest heavily in DMD drug development. The expanding clinical trial pipeline, supported by collaborations between academic institutions, biotechnology firms, and patient advocacy groups, is accelerating the translation of novel compounds from preclinical stages to commercial availability, thereby propelling the duchenne muscular dystrophy drugs market growth across all major regions.

The United States has emerged as a major region in the duchenne muscular dystrophy drugs market owing to many factors. The country possesses a robust pharmaceutical research ecosystem, with leading academic medical centers and biotechnology companies dedicating substantial resources to neuromuscular disease therapies. Supportive federal policies, including the Orphan Drug Act and expedited review pathways, have incentivized drug development for rare conditions like DMD. For instance, the FDA expanded the approval of ELEVIDYS (delandistrogene moxeparvovec) in 2024, making it available as a gene therapy for ambulatory and non-ambulatory individuals aged four years and older with confirmed DMD gene mutations. Additionally, comprehensive newborn screening programs and advanced diagnostic capabilities are enabling earlier identification of affected patients, which supports timely therapeutic intervention and drives the market growth across the nation.

DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET TRENDS:

Advancements in Gene Therapy Approaches

The rapid evolution of gene therapy technologies is significantly reshaping the therapeutic landscape for Duchenne muscular dystrophy. Researchers are leveraging adeno-associated virus vectors to deliver functional micro-dystrophin genes directly into muscle tissue, aiming to restore partial dystrophin production and slow disease progression. These single-dose intravenous infusion therapies represent a paradigm shift from chronic symptomatic management to potentially durable disease-modifying interventions. Additionally, the development of CRISPR-based gene editing platforms is opening new avenues for precise correction of dystrophin gene mutations, with several candidates advancing through preclinical evaluation. For instance, in June 2025, the FDA granted Rare Pediatric Disease Designation to PBGENE-DMD, an in vivo gene editing therapy by Precision BioSciences developed using the ARCUS platform, which targets exons 45 to 55 of the dystrophin gene and holds the potential to benefit up to 60 percent of DMD patients. These breakthroughs are attracting substantial investment and regulatory support globally.

Rising Adoption of Novel Corticosteroids

The introduction of next-generation corticosteroids with improved safety profiles is transforming the standard of care for DMD patients and supporting the duchenne muscular dystrophy drugs market forecast. Traditional corticosteroids such as prednisone and deflazacort have long been the cornerstone of DMD management, providing meaningful benefits in preserving muscle function and delaying loss of ambulation. However, their prolonged use is associated with significant adverse effects including growth stunting, bone density loss, and behavioral changes. Novel dissociative corticosteroids have been developed to retain anti-inflammatory efficacy while minimizing these side effects through selective receptor modulation. For instance, in November 2025, Santhera Pharmaceuticals reported positive five-year data from its GUARDIAN study of vamorolone (Agamree), demonstrating durable efficacy comparable to standard corticosteroids with significantly lower rates of vertebral fractures and improved growth trajectories in DMD patients. These clinical advantages are increasing prescribers' confidence and patient adoption worldwide.

Expanding Nonsteroidal Treatment Options

The approval and development of nonsteroidal therapies are diversifying the DMD treatment arsenal and addressing the duchenne muscular dystrophy drugs market trends. Histone deacetylase inhibitors represent a novel mechanistic approach that targets the downstream pathological processes caused by dystrophin deficiency, including chronic inflammation, impaired muscle regeneration, and progressive fat infiltration. These agents work by modulating gene expression to restore essential cellular repair mechanisms in dystrophic muscle tissue, offering benefits independent of the underlying genetic mutation type. The availability of treatments effective across all genetic variants of DMD is particularly significant, as it expands the eligible patient population beyond mutation-specific therapies. For instance, in April 2025, the European Medicines Agency's CHMP adopted a positive opinion recommending conditional marketing authorisation for Duvyzat (givinostat) by Italfarmaco for DMD patients aged six years and older who are ambulatory. This development follows the FDA approval of givinostat in March 2024, positioning it as a complementary treatment option alongside corticosteroid regimens.

DUCHENNE MUSCULAR DYSTROPHY DRUGS INDUSTRY SEGMENTATION:

Analysis by Product Type:

  • Corticosteroids
    • Prednisolone
    • Prednisone
    • Deflazacort
  • Pain Management Drugs

Corticosteroids holds 65% of the market share. Corticosteroids constitute the most widely prescribed class of drugs for managing DMD, owing to their well-established efficacy in slowing disease progression and preserving motor function. These medications work by reducing inflammation and modulating immune responses within dystrophic muscle tissue, thereby delaying the onset of critical milestones such as loss of ambulation and respiratory decline. Prednisone, prednisolone, and deflazacort remain the primary treatment options within this category, each offering distinct pharmacological profiles suited to individual patient needs. The extensive clinical experience and strong body of evidence supporting corticosteroid therapy have solidified their role as a cornerstone of Duchenne muscular dystrophy (DMD) management worldwide. Ongoing advancements in steroid formulations aim to preserve anti-inflammatory efficacy while minimizing the side effects commonly associated with traditional corticosteroids, further strengthening their importance in long-term DMD treatment strategies.

Analysis by Therapeutic Approach:

  • Mutation Suppression
  • Exon Skipping
  • Steroid Therapy

Exon Skipping leads the market with a share of 40%. Exon skipping therapies represent a targeted molecular approach that uses antisense oligonucleotides to modify pre-messenger RNA splicing, enabling the production of a truncated but partially functional dystrophin protein. This therapeutic strategy addresses specific exon mutations in the dystrophin gene, making it applicable to defined patient subpopulations based on their genetic profiles. The FDA has approved multiple exon skipping therapies targeting different exon mutations, including eteplirsen for exon 51, golodirsen for exon 53, and casimersen for exon 45 skipping. These approvals have collectively expanded treatment eligibility to a significant proportion of the DMD patient population. For instance, in July 2025, the FDA granted Breakthrough Therapy designation to delpacibart zotadirsen by Avidity Biosciences, a novel Antibody Oligonucleotide Conjugate designed for DMD patients with mutations amenable to exon 44 skipping, marking the first such conjugate in development for DMD.

Analysis by End User:

  • Hospitals
  • Clinics
  • Home Care Settings

Hospitals dominate the market, with a share of 48%. Hospitals serve as the primary setting for DMD drug administration and patient management due to the complex nature of the disease and the specialized infrastructure required for advanced therapies. Gene therapies, particularly intravenous infusion-based treatments, necessitate hospital-based delivery with comprehensive monitoring capabilities to manage potential immune-mediated adverse events and ensure patient safety. Furthermore, hospitals house multidisciplinary care teams comprising neurologists, pulmonologists, cardiologists, and rehabilitation specialists who coordinate comprehensive treatment plans for DMD patients across all disease stages. The growing number of designated neuromuscular centers of excellence within hospital networks is strengthening the hospital segment's position, thereby creating a positive duchenne muscular dystrophy drugs market outlook. For instance, in May 2025, Sarepta Therapeutics reported that its ENDEAVOR study participants aged two years at treatment showed mean micro-dystrophin expression of 93.87 percent of normal levels in hospital-administered ELEVIDYS infusions.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America, accounting for 35% of the share, enjoys the leading position in the market. The region's dominance is attributed to its advanced healthcare infrastructure, strong pharmaceutical research and development ecosystem, and favorable regulatory environment that expedites the approval of novel DMD therapies through orphan drug designations and accelerated review pathways. Comprehensive insurance coverage systems and robust reimbursement frameworks in the United States and Canada ensure widespread patient access to high-cost treatments, including gene therapies and specialty pharmaceuticals. The presence of leading biotechnology companies and research institutions dedicated to neuromuscular disease innovation further strengthens the regional market. For instance, Sarepta Therapeutics reported net product revenue of USD 370 million for the third quarter of 2025, driven by strong commercial uptake of its DMD portfolio including ELEVIDYS gene therapy and three approved exon skipping treatments across North America.

KEY REGIONAL TAKEAWAYS:

United States Duchenne Muscular Dystrophy Drugs Market Analysis

The United States represents the largest individual market for DMD therapies globally, underpinned by a sophisticated healthcare system, extensive clinical trial infrastructure, and high rates of disease awareness and early diagnosis. The regulatory landscape in the United States is particularly conducive to rare disease drug development, with the FDA offering multiple incentive mechanisms including orphan drug exclusivity, priority review vouchers, and breakthrough therapy designations that accelerate the path from clinical development to market authorization. The country's well-developed private insurance market and government healthcare programs provide substantial coverage for specialty pharmaceuticals, enabling patient access to therapies that carry annual costs ranging from several hundred thousand to over three million dollars per treatment. For instance, approximately 15,000 individuals in the United States are currently living with DMD, creating a concentrated patient population that drives sustained therapeutic demand and innovation investment. The robust presence of leading DMD-focused companies, extensive neuromuscular care networks, and ongoing expansion of newborn screening programs further reinforce the United States as the primary driver of market expansion within the region.

Europe Duchenne Muscular Dystrophy Drugs Market Analysis

Europe represents a significant market for DMD therapeutics, supported by strong regulatory frameworks, well-funded public healthcare systems, and a growing emphasis on rare disease research across the continent. The European Medicines Agency is in the position of centralizing access to novel DMD treatments by conditional marketing authorities and orphan medicinal product designation to stimulate pharmaceutical development. The major markets include countries like Germany, the United Kingdom, France, and Italy, and each of them possesses specialized expertise in managing neuromuscular diseases and research in clinical research. Early DMD cases are being enhanced by national screening programs and the genetic diagnostic capacity of European states, which facilitates prompt initiation of treatment. The cooperative research climate in the continent, facilitated by Telethon and other national rare disease associations' initiatives, remains in progress to increase the therapeutic pipeline and clinical care of DMD patients.

Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Analysis

Asia-Pacific is emerging as a rapidly growing market for DMD therapeutics, driven by improving healthcare infrastructure, increasing disease awareness, and expanding access to advanced treatment modalities across the region. Japan stands at the forefront of DMD innovation in the Asia-Pacific, with an efficient regulatory framework and strong government support for rare disease management. Countries including China, India, South Korea, and Australia are witnessing greater diagnostic capabilities and rising adoption of specialty pharmaceuticals for neuromuscular conditions. For instance, in September 2025, the Ministry of Health, Labour and Welfare in Japan granted Orphan Drug designation for DYNE-251 by Dyne Therapeutics, intended for individuals with DMD carrying mutations amenable to exon 51 skipping. Government-led initiatives to integrate genomic medicine into clinical practice and expand clinical trial participation across the region are expected to accelerate market development.

Latin America Duchenne Muscular Dystrophy Drugs Market Analysis

Latin America represents a growing market for DMD therapeutics as healthcare systems across the region progressively expand access to specialized treatments for rare neuromuscular diseases. Countries such as Brazil and Mexico are leading regional efforts to improve diagnostic infrastructure and therapeutic availability for DMD patients. Growing government focus on rare disease frameworks and the development of specialized reference centers for neuromuscular disorders are enhancing early diagnosis and comprehensive patient management. In Latin America, efforts to strengthen disease awareness, expand screening initiatives, and streamline referral pathways are helping reduce diagnostic delays and improve access to appropriate care for individuals affected by Duchenne muscular dystrophy.

Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Analysis

The Middle East and Africa region presents emerging opportunities for DMD drug market development, driven by gradually improving healthcare infrastructure and rising awareness of genetic neuromuscular disorders. Several Gulf Cooperation Council nations are investing in advanced medical facilities and genetic diagnostic capabilities to address rare diseases including DMD. Strategic collaborations between regional healthcare providers and international research institutions are promoting knowledge exchange and strengthening clinical capabilities. These partnerships support improved diagnostic standards, training programs, and access to specialized care. Expanding awareness and treatment infrastructure is particularly important in underserved areas of the Middle East and Africa, where enhancing early detection and comprehensive management of Duchenne muscular dystrophy remains a growing priority.

COMPETITIVE LANDSCAPE:

The competitive landscape of the DMD drugs market is characterized by intense research activity and strategic collaborations among pharmaceutical and biotechnology companies focused on advancing novel therapeutic modalities. Key market participants are investing substantially in gene therapy platforms, exon skipping technologies, and nonsteroidal anti-inflammatory agents to address the significant unmet medical needs of DMD patients. Companies are pursuing diverse strategies including portfolio expansion through pipeline development, regulatory milestone achievements across multiple geographies, and commercial partnerships to enhance market penetration. The competitive environment is further shaped by the high cost of advanced therapies, evolving reimbursement frameworks, and ongoing safety monitoring requirements that influence market positioning. Strategic acquisitions, licensing agreements, and collaborative research programs with academic institutions and patient advocacy organizations continue to drive innovation and competitive differentiation across the market.

The report provides a comprehensive analysis of the competitive landscape in the duchenne muscular dystrophy drugs market with detailed profiles of all major companies, including:

  • FibroGen Inc.
  • Italfarmaco S.p.A.
  • NS Pharma Inc. (Nippon Shinyaku Co. Ltd.)
  • PTC Therapeutics Inc.
  • Santhera Pharmaceuticals
  • Sarepta Therapeutics Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the duchenne muscular dystrophy drugs market?

2. What is the future outlook of duchenne muscular dystrophy drugs market?

3. What are the key factors driving the duchenne muscular dystrophy drugs market?

4. Which region accounts for the largest duchenne muscular dystrophy drugs market share?

5. Which are the leading companies in the global duchenne muscular dystrophy drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Duchenne Muscular Dystrophy Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Corticosteroids
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Prednisolone
      • 6.1.2.2 Prednisone
      • 6.1.2.3 Deflazacort
    • 6.1.3 Market Forecast
  • 6.2 Pain Management Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Therapeutic Approach

  • 7.1 Mutation Suppression
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Exon Skipping
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Steroid Therapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Home Care Settings
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 FibroGen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Italfarmaco S.p.A.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 NS Pharma Inc. (Nippon Shinyaku Co. Ltd.)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 PTC Therapeutics Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Santhera Pharmaceuticals
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Sarepta Therapeutics Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Duchenne Muscular Dystrophy Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Product Type (in %), 2025
  • Figure 5: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Therapeutic Approach (in %), 2025
  • Figure 6: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by End User (in %), 2025
  • Figure 7: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Duchenne Muscular Dystrophy Drugs (Corticosteroids) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Duchenne Muscular Dystrophy Drugs (Corticosteroids) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Duchenne Muscular Dystrophy Drugs (Pain Management Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Duchenne Muscular Dystrophy Drugs (Pain Management Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Duchenne Muscular Dystrophy Drugs (Mutation Suppression) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Duchenne Muscular Dystrophy Drugs (Mutation Suppression) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Duchenne Muscular Dystrophy Drugs (Exon Skipping) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Duchenne Muscular Dystrophy Drugs (Exon Skipping) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Duchenne Muscular Dystrophy Drugs (Steroid Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Duchenne Muscular Dystrophy Drugs (Steroid Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Duchenne Muscular Dystrophy Drugs (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Duchenne Muscular Dystrophy Drugs (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Duchenne Muscular Dystrophy Drugs (Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Duchenne Muscular Dystrophy Drugs (Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Duchenne Muscular Dystrophy Drugs (Home Care Settings) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Duchenne Muscular Dystrophy Drugs (Home Care Settings) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: North America: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: North America: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: United States: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: United States: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Canada: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Canada: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Asia-Pacific: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Asia-Pacific: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: China: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: China: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Japan: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Japan: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: India: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: India: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: South Korea: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: South Korea: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Australia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Australia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Indonesia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Indonesia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Europe: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Europe: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Germany: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Germany: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: France: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: France: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: United Kingdom: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: United Kingdom: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Italy: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Italy: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Spain: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Spain: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Russia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Russia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Latin America: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Latin America: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Brazil: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Brazil: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Mexico: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Mexico: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market: Breakup by Country (in %), 2025
  • Figure 72: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Global: Duchenne Muscular Dystrophy Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 74: Global: Duchenne Muscular Dystrophy Drugs Industry: Value Chain Analysis
  • Figure 75: Global: Duchenne Muscular Dystrophy Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Duchenne Muscular Dystrophy Drugs Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Product Type (in Million USD), 2026-2034
  • Table 3: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Therapeutic Approach (in Million USD), 2026-2034
  • Table 4: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Duchenne Muscular Dystrophy Drugs Market: Competitive Structure
  • Table 7: Global: Duchenne Muscular Dystrophy Drugs Market: Key Players